story of the week
ctDNA Mutation Tracking to Detect MRD and Trigger Intervention in Patients With Moderate- and High-Risk Early-Stage TNBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate and high-risk early stage triple negative breast cancer
Ann. Oncol 2022 Nov 21;[EPub Ahead of Print], NC Turner, C Swift, B Jenkins, L Kilburn, M Coakley, M Beaney, L Fox, K Goddard, I Garcia-Murillas, P Proszek, P Hall, CH Wynne, T Hickish, S Kernaghan, IR Macpherson, A Okines, C Palmieri, S Perry, K Randle, C Snowdon, H Stobart, A Wardley, D Wheatley, S Waters, M Winter, M Hubank, S Allen, JM BlissFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.